Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Sep. 2025,
Ping An Biomedical Co paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It spent$8.97 Mil paying down its debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$14.82 Mil on other financial activities.
In all, Ping An Biomedical Coearned$5.85 Mil on financial activities for the
six
months ended in Sep. 2025.
Ping An Biomedical Co (NAS:PASW) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Ping An Biomedical Co's issuance of stock for the
six
months ended in Sep. 2025 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Ping An Biomedical Co's repurchase of stock for the
six
months ended in Sep. 2025 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Ping An Biomedical Co's net issuance of debt for the
six
months ended in Sep. 2025 was $-8.97 Mil.
Ping An Biomedical Co spent$8.97 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Ping An Biomedical Co's net issuance of preferred for the
six
months ended in Sep. 2025 was $0.00 Mil.
Ping An Biomedical Co paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Ping An Biomedical Co's cash flow for dividends for the
six
months ended in Sep. 2025 was $0.00 Mil.
Ping An Biomedical Co received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Ping An Biomedical Co's other financing for the
six
months ended in Sep. 2025 was $14.82 Mil.
Ping An Biomedical Co received$14.82 Mil on other financial activities.
Ping An Biomedical Co Cash Flow from Financing Related Terms
Ping An Biomedical Co Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Ping An Biomedical Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ping An Biomedical Co Cash Flow from Financing Chart
Ping An Biomedical Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Ping An Biomedical Co's Cash from Financing for the fiscal year that ended in Sep. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $6.12 Mil mean?
Ping An Biomedical Co (PASW) has a Cash Flow from Financing of $6.12 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ping An Biomedical Co and its competitors.
Is Ping An Biomedical Co's Cash Flow from Financing too high?
Ping An Biomedical Co's current Cash Flow from Financing is $6.12 Mil. Overall, Ping An Biomedical Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ping An Biomedical Co's Cash Flow from Financing compare to DXYN and CULP?
Ping An Biomedical Co's Cash Flow from Financing of $6.12 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Manufacturing - Apparel & Accessories company?
A good Cash Flow from Financing depends on the Manufacturing - Apparel & Accessories industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Ping An Biomedical Co and its competitors. Ping An Biomedical Co's current Cash Flow from Financing is $6.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ping An Biomedical Co stock overvalued right now?
Ping An Biomedical Co (PASW) has a current Cash Flow from Financing of $6.12 Mil. The current Cash Flow from Financing is $6.12 Mil. Ping An Biomedical Co's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Ping An Biomedical Co (PASW), the current Cash Flow from Financing is $6.12 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
17GF Score
Get the complete analysis for PASW
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASW has been successfully added to your 
